NASDAQ:BVXV
Delisted
BiondVax Pharmaceuticals Ltd. Stock News
$1.36
+0 (+0%)
At Close: Dec 05, 2023
BiondVax Announces Pricing of $12.1 Million Follow-on Underwritten Offering of American Depositary Shares
07:57am, Friday, 29'th Jan 2021
JERUSALEM, Jan. 29, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the
BiondVax Announces Third Quarter 2020 Financial Results & Business Update
03:23pm, Thursday, 28'th Jan 2021
JERUSALEM, Jan. 28, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the
BiondVax Announces Appointment of Amir Reichman as New CEO
07:15am, Thursday, 21'st Jan 2021
JERUSALEM, Jan. 21, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on development and manufacturing of products for the prevention and treatment
BiondVax Pharmaceuticals: A Small, Undervalued Biotech Company
06:21pm, Tuesday, 01'st Sep 2020
A small Israeli company with world-class science is leading the way to a first-in-kind universal influenza vaccine that could provide lasting immunity to all forms of influenza.
BiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Clinical Trial Update
08:01pm, Thursday, 13'th Aug 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the Phase 3 clinical trial M–001 universal influenza vaccine candidate, today announced that the Annual General Meeting of Shareholders of
Vaccine Makers BioNTech, Moderna, And Novavax Set To Run Higher
12:00am, Tuesday, 14'th Jul 2020
Stocks Analysis by Harry Boxer covering: KB Home, Vaxart Inc, Novavax Inc, Altimmune Inc. Read Harry Boxer's latest article on Investing.com
The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
12:00am, Friday, 10'th Jul 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 9)
Affimed NV (NASDAQ: AFMD)...
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
12:00am, Thursday, 09'th Jul 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 8)
Akero Therapeutics Inc (...
6 Stocks That Could Pop Higher
12:00am, Wednesday, 08'th Jul 2020
Stocks Analysis by Harry Boxer covering: BioCryst Pharmaceuticals Inc, Cytokinetics Inc, Vaxart Inc, Novavax Inc. Read Harry Boxer's latest article on Investing.com
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 6)
ACADIA Pharmaceuticals Inc...
Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial
10:00am, Wednesday, 01'st Jul 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today announced that all participants in the placebo-controlled, blinded, pivotal, clinical efficacy, Phase 3 trial of BiondVax's M–001 universal influen
BiondVax Announces First Quarter 2020 Financial Results
08:01pm, Tuesday, 30'th Jun 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza vaccine candidate, today announced its f
BVXV: Positive Results in NIH-Sponsored Phase 2 Trial of M-001; Raising Valuation to $81…
12:57pm, Tuesday, 16'th Jun 2020
By David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT Business Update Topline Results from Phase 3 Trial of M-001 Expected by End of 2020 BiondVax Pharmaceuticals, Ltd. (NASDAQ:BVXV) is a
BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
12:00pm, Friday, 12'th Jun 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza vaccine candidate, today announced its f
NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved
11:00am, Wednesday, 10'th Jun 2020
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today announced the completion of the clinical study report (CSR) of a Phase 2 clinical trial of the Company's M-001 universal influenza vaccine candidate.
